
Vaccine maker Moderna's (NASDAQ: MRNA) stock prices fell by over 16% on 13th January to close at £28.81 ($35.15) after the company trimmed its 2025 revenue guidance to between £1.22 billion ($1.5 billion) and £2.04 billion ($2.5 billion) from its previous estimate between £2.04 billion ($2.5 billion) and £2.86 billion ($3.5 billion).
Wall Street expected a sales outlook of £2.39 billion ($2.92 billion). One year ago, analysts predicted Moderna's 2025 sales to reach £4.1 billion ($5 billion).